FDA
-
-
-
-
-
-
-
Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results
-
-
-
-
-
-
-
Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research
-
-
-
-
-
-
-
Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs
-
-
-
-
-
-
-
Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlights
-
-
-
326,462 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

